SCHEMBL31662335

SCHEMBL31662335

COc1ncc(F)c2nc(OC[C@@]34CCCN3C[C@H](F)C4)nc(O)c12

nearest known ligand 0.47

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662293 0.83 KRAS (0.42) KRAS
SCHEMBL30702881 0.83 KRAS (0.45) KRAS
SCHEMBL31691620 0.81 KRAS (0.51) KRAS
SCHEMBL31662292 0.80 KRAS (0.51) KRAS
SCHEMBL29937188 0.79 KRAS (0.50) KRAS
SCHEMBL30825596 0.78 KRAS (0.51) KRAS
SCHEMBL30998741 0.77 KRAS (0.51) KRAS
SCHEMBL26691313 0.77 KRAS (0.54) KRAS
SCHEMBL30922549 0.76 KRAS (0.55) KRAS
SCHEMBL25401732 0.76 KRAS (0.45) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 — — WO disclosed
Send feedback